Magnetic Resonance Imaging Response Monitoring of Breast Cancer During Neoadjuvant Chemotherapy: Relevance of Breast Cancer Subtype
Claudette E. Loo(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital), Kenneth G. A. Gilhuijs(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital), Marieke E. Straver(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital), Sara Müller(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital), Sjoerd Rodenhuis(The Netherlands Cancer Institute), Marie-Jeanne T. F. D. Vrancken Peeters(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital), Jelle Wesseling(Leiden University Medical Center)
Cited by 306
Related Papers
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
|New England Journal of Medicine|2002|6.5k
K-<i>ras</i>Oncogene Activation as a Prognostic Marker in Adenocarcinoma of the Lung
|New England Journal of Medicine|1990|811
Impairment of Cognitive Function in Women Receiving Adjuvant Treatment for High-Risk Breast Cancer: High-Dose Versus Standard-Dose Chemotherapy
|JNCI Journal of the National Cancer Institute|1998|768
Mutational Activation of the K-<i>ras</i>Oncogene
|New England Journal of Medicine|1987|540